Tirzepatide for hot flashes in postmenopausal women with obesity
Treatments studied
Part of Hormones & metabolism clinical trials.
This study tests whether tirzepatide, a weekly injection, can reduce hot flashes and slow biological aging in postmenopausal women with obesity. It may help if you are experiencing bothersome hot flashes and are willing to follow a diet and exercise plan.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 46 to 60.
- Your body mass index (BMI) is 30 or higher, or 27 or higher with conditions like high blood pressure or sleep apnea.
- You have bothersome hot flashes, averaging at least 28 episodes over two weeks, and they have lasted more than 30 days.
- You are willing to inject the medication yourself once a week.
- You are willing to follow a reduced-calorie diet and do at least 150 minutes of moderate exercise per week.
- You have not used hormone therapy or other menopause treatments in the past 4 weeks.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a GLP-1 agonist medication (like Ozempic) to help postmenopausal women lose weight and improve physical and blood vessel health. It focuses on women aged 46–60 with obesity.
This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.
This trial tests a once-weekly injection called tirzepatide to help people with obesity and severe knee osteoarthritis lose weight and potentially reduce knee pain. It may be a good option if you're already waiting for knee replacement surgery and have struggled to lose weight in the past.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
This study tests if tirzepatide helps people with obesity lose weight, whether or not they have type 2 diabetes. It aims to see how safe and effective the drug is.
This study tests a medication called tirzepatide (a once-weekly injection) to help teenagers with obesity and related health conditions lose weight. It aims to see if the drug is safe and effective for this age group.
Hear when a new Obesity trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.